202 related articles for article (PubMed ID: 12428992)
1. Hormone replacement therapy: optimising the dose and route of administration.
Montgomery Rice V
Drugs Aging; 2002; 19(11):807-18. PubMed ID: 12428992
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the dose of hormone replacement therapy.
Rice VM
Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms.
Botteman MF; Shah NP; Lian J; Pashos CL; Simon JA
Menopause; 2004; 11(3):343-55. PubMed ID: 15167315
[TBL] [Abstract][Full Text] [Related]
5. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
[TBL] [Abstract][Full Text] [Related]
7. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
[TBL] [Abstract][Full Text] [Related]
8. [Basic principles of hormone replacement therapy in the postmenopause].
Dören M
Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
[TBL] [Abstract][Full Text] [Related]
11. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women.
Cummings JA; Brizendine L
Menopause; 2002; 9(4):253-63. PubMed ID: 12082361
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
14. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.
Nelson HD
JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049
[TBL] [Abstract][Full Text] [Related]
15. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
[TBL] [Abstract][Full Text] [Related]
17. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
Palacios S
Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
[TBL] [Abstract][Full Text] [Related]
18. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of osteoporosis by the gynecologist].
Schneider HP; Dören M
Zentralbl Gynakol; 1994; 116(12):691-4. PubMed ID: 7846982
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
